Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Business News: AbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Business News: AbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

– Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for patients who are ineligible for intensive chemotherapy

– VENCLEXTA is now approved in the U.S. for use in two different blood cancers: newly-diagnosed AML and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)

– The approval in AML is the third provided under priority review by the U.S.

Continue reading Business News: AbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy at STL.News.



This post first appeared on STL.News, please read the originial post: here

Share the post

Business News: AbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

×

Subscribe to Stl.news

Get updates delivered right to your inbox!

Thank you for your subscription

×